Core Viewpoint - The article highlights the successful A+ round financing of Pulsecare, emphasizing the recognition of its innovative technology in the cardiovascular intervention field and the significant clinical value of its NxPFA® system [3][4]. Financing and Investment - Pulsecare completed a significant financing round led by Yuanhe Origin, with participation from Zhengxin Valley Capital and existing shareholders [3]. - The funds raised will be used to accelerate the commercialization of the NxPFA® system and advance clinical research for its muRDN system [4][9]. Product Innovation - The NxPFA® system is the world's first and only approved nsPFA product, marking a new era in pulsed field ablation technology [5]. - The system offers significant advantages over previous technologies, including reduced nerve stimulation and improved safety and efficacy [5][6]. - The company is also developing a comprehensive cardiac electrophysiology solution that integrates 3D mapping, PFA, and ICE technologies [6]. Clinical Research and Development - The NxPFA® system has demonstrated a 100% immediate isolation rate of pulmonary veins and an 88.27% success rate one year post-operation in clinical studies [5]. - The muRDN system is in the registration phase, aiming to provide a breakthrough in hypertension treatment [7]. Market Potential - The article discusses the growing market potential for PFA and RDN technologies, with expectations of rapid revenue growth and market expansion [9]. - The company aims to leverage its innovative products to establish a strong presence in the global cardiovascular market [10]. Company Vision and Strategy - Pulsecare is committed to continuous innovation and integration of technology in the medical field, focusing on addressing clinical pain points and enhancing treatment value [8]. - The company plans to expand its global footprint and contribute to the prevention and control of cardiovascular diseases worldwide [8].

Core Insights - Maiwei Medical has successfully completed a Series A+ financing round, raising over 1 billion RMB, led by Yuanhe Origin with participation from Zhengxin Valley Capital and existing shareholders Tianfeng Capital and Waterwood Venture [1] - The funds will be primarily used to accelerate the commercialization of its core product, the NxPFA® nanosecond pulsed electric field ablation system, and to advance the development of comprehensive cardiac electrophysiology solutions based on nsPFA technology [1] - Maiwei Medical focuses on innovative medical devices for cardiovascular multimodal treatment, having developed multiple innovative products and solutions for conditions such as atrial fibrillation and resistant hypertension since its establishment in July 2021 [1] Product Development - The NxPFA® nanosecond pulsed electric field ablation system is expected to receive approval from the National Medical Products Administration (NMPA) by July 2025, becoming the world's first and only approved nsPFA product, marking a significant advancement in the field [1] - In the field of hypertension intervention, Maiwei Medical's muRDN™ ultrasound renal denervation system has entered the registration verification phase after successfully enrolling its first patient in the ModulationHTN-2 multicenter clinical study in June 2025 [2] - The muRDN system, along with the NxPFA® system, aims to create a "heart-kidney interaction" intervention loop, enhancing the management of atrial fibrillation and hypertension, and contributing to a strategic upgrade towards comprehensive cardiovascular management for millions of patients globally [2]